Shah S S, Sinkowitz-Cochran R L, Keyserling H L, Jarvis W R
Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, GA 30333, USA.
Am J Infect Control. 1999 Dec;27(6):482-7. doi: 10.1016/s0196-6553(99)70025-8.
The objective of this article is to describe a pediatric neurosurgery patient population receiving vancomycin and examine the indications for and appropriateness of vancomycin use.
A cross-sectional study was performed on the pediatric neurosurgery patients at Egleston Children's Hospital who received vancomycin from January 1 through December 31, 1996. Vancomycin use was compared with the Centers for Disease Control and Prevention Hospital Infection Control Practices Advisory Committee recommendations for vancomycin use.
Thirty patients received 115 doses of vancomycin. The median patient age was 8.0 years, and 17 (56.7%) were male. Vancomycin was used for prophylaxis in 28 (93.3%) patients and empiric therapy in 3 (10.0%) patients; one patient received vancomycin for surgical prophylaxis followed by empiric therapy for suspected meningitis. Vancomycin prophylaxis was initiated after the incision in 6 (21.4%) patients and was continued as prophylaxis for more than one dose in 26 (92.9%) patients.
Vancomycin was used primarily as surgical prophylaxis in pediatric neurosurgery patients, and use was not consistent with the Hospital Infection Control Practices Advisory Committee recommendations. These data suggest that for certain subpopulations, such as pediatric neurosurgery patients, there is a need for more specialized recommendations. Furthermore, prudent vancomycin use is warranted to successfully decrease the risk of further emergence of vancomycin resistance. Because vancomycin use may be prevalent in this population, assessment of vancomycin use in pediatric neurosurgery patients followed by establishment of vancomycin clinical guidelines may help improve the appropriateness of vancomycin use in this population.
本文旨在描述接受万古霉素治疗的儿科神经外科患者群体,并探讨使用万古霉素的指征及合理性。
对1996年1月1日至12月31日在埃格尔斯顿儿童医院接受万古霉素治疗的儿科神经外科患者进行了一项横断面研究。将万古霉素的使用情况与疾病控制和预防中心医院感染控制实践咨询委员会关于万古霉素使用的建议进行了比较。
30名患者共接受了115剂万古霉素。患者的中位年龄为8.0岁,其中17名(56.7%)为男性。28名(93.3%)患者使用万古霉素进行预防,3名(10.0%)患者进行经验性治疗;1名患者先使用万古霉素进行手术预防,随后因疑似脑膜炎进行经验性治疗。6名(21.4%)患者在切口后开始使用万古霉素进行预防,26名(92.9%)患者持续使用一剂以上进行预防。
万古霉素在儿科神经外科患者中主要用作手术预防,其使用与医院感染控制实践咨询委员会的建议不一致。这些数据表明,对于某些亚群体,如儿科神经外科患者,需要更专门的建议。此外,谨慎使用万古霉素对于成功降低万古霉素耐药性进一步出现的风险是必要的。由于万古霉素在该群体中的使用可能较为普遍,对儿科神经外科患者的万古霉素使用情况进行评估,随后制定万古霉素临床指南,可能有助于提高该群体中万古霉素使用的合理性。